The collaboration leverages Insilico's end-to-end AI-driven Pharma.AI platform to discover novel small molecule drug candidates for multiple targets, along with EQRx's innovative business model to accelerate drug development and patient access to novel medicines at affordable prices
Sputnik Light is the first component of Sputnik V
At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide
The USFDA has granted a qualified infectious disease product (QIDP) designation to WCK 6777, which signifies its ability to meet unmet medical needs and facilitates a faster approval process
The investment will accelerate the overall Sarclisa development program
MTBVAC is a global public-private project that will be a milestone in the field of vaccinology
Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial
The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers
This collaboration has resulted in several high-impact scientific publications describing breakthrough inventions, including the SOMA robotic pill, which has subsequently been licensed exclusively to Novo Nordisk for clinical development
With over 20 years of international leadership experience, Dr. Amrein has led many teams and organizations across over 30 geographies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
